Abstract
Immunosuppressive drugs have been used to treat patients with severe rheumatoid arthritis for the last thirty years. The drugs commonly used are cyclophosphamide and chlorambucil (alkylating agents), azathioprine (purine analogue) and methotrexate (folic acid analogue). A Medline search and review articles were used to identify clinical trials of these drugs in patients with rheumatoid arthritis. A scoring system was used to assess the design and execution of these trials.
There is evidence that all four immunosuppressive drugs studied can reduce synovitis assessed by a range of clinical measurements. The occurrence of spontaneous remissions in rheumatoid arthritis, and the known response to bed rest and anti-inflammatory drugs, render the results obtained from controlled trials of cyclophosphamide and azathioprine more convincing. Reports on the use of immunosuppressive drugs for severe vasculitic manifestions of rheumatoid arthritis are largely confined to case reports. These suggest that cylcophosphamide and chlorambucil are effective in these patients, but azathioprine was found to be ineffective in one trial. Cyclophosphamide, but not other drugs, has been shown to retard radiographic progression of joint destruction.
Adverse effects occurring with all four drugs include bone marrow depression, gastro-intestinal symptoms, rashes and increased susceptibility to infections. Data on the possible increased risk of malignancy in patients treated with immunosuppressive drugs for non-malignant conditions are still being collected; cautious interpretation is required because of the excess frequency of lymphoproliferative malignancy in patients with rheumatoid arthritis.
Until further information is available, use of immunosuppressive drugs, particularly alkylating agents, in rheumatoid arthritis should be confined to patients with life-threatening complications such as severe vasculitis and patients with severe progressive joint disease.
Preview
Unable to display preview. Download preview PDF.
References
Jimenez Diaz, C. ‘Treatment of dysreaction diseases with nitrogen mustards’, Ann. Rheum. Dis. 10 (1951) 144–51.
Denman, A. M. ‘Immunosuppression and the rheumatic diseases’, Ann. Rheum. Dis. 41 (Suppl. 1) (1982) 3–8.
Kovarsky, J. ‘Clinical pharmacology and toxicology of cyclophosphamide: emphasis on use in rheumatic diseases’, Sem. Arthritis Rheum. 12 (1983) 359–72.
Ibid.
Amor, B. and Mery, C. ‘Chlorambucil in rheumatoid arthritis’, Clin. Rheum. Dis. 6 (1980) 567–84.
Turk, J. L. and Poulter, L. W. ‘Selective depletion of lymphoid tissue by cyclophosphamide’, Clin. Exp. Immunol. 10 (1972) 285–96.
Lagrange, P. H., Mackannes, G. B. and Miller, T. E. ‘Potentiation of T-cell-mediated immunity by selective suppression of antibody formation with cyclophosphamide’, J. Exp. Med. 139 (1974) 1529–39.
Many, A. and Schwartz, R. S. ‘On the mechanism of immunological tolerance in cyclophosphamide-treated mice’, Clin. Exp. Immunol. 6 (1970) 87–99.
Turk, J. L. and Parker, D. ‘Effect of cyclophosphamide on immunological control mechanisms’, Immunol. Rev. 65 (1982) 99–113.
Kawaguchi, S. ‘Studies on the induction of immunological paralysis to bovine 7-globulin in adult mice. II. The effect of cyclophosphamide’, Immunol. 19 (1970) 291–9.
Stevenson, H. C. and Fauci, A. S. ‘Activation of human B lymphocytes. XII. Differential effects of in vitro cyclophosphamide on human lymphocyte sub-populations involved in B cell activation’, Immunol. 39 (1980) 391–7.
Cooperating Clinics Committee of the American Rheumatism Association, ‘A controlled trial of cyclophosphamide in rheumatoid arthritis’, New Engl. J. Med. 283 (1970) 883–95.
Townes, A. S., Sowa, J. M. and Shulman, L. E. ‘Controlled trial of cyclophosphamide in rheumatoid arthritis’, Arthritis Rheum. 19 (1976) 563–73.
Alepa, F. P., Zvaifler, N. J. and Sliwinski, A. J. ‘Immunologic effects of cyclophosphamine treatment in rheumatoid arthritis’, Arthritis Rheum. 13 (1970) 754–60.
Clements, P. J., Yu, D. T., Levy, J., Paulus, H. E. and Barnett, E. V. ‘Effects of cyclophosphamide on B and T lymphocytes in rheumatoid arthritis’, Arthritis Rheum. 17 (1974) 347–53.
Hurd, E. R. and Ziff, M. ‘Parameters of improvement in patients with rheumatoid arthritis treated with cyclophosphamide’, Arthritis Rheum. 17 (1974) 72–8.
Berry, H., Liyanage, S. P., Durance, R. A., Barnes, C. G., Berger, L. A. and Evans, S. ‘Azathioprine and penicillamine in treatment of rheumatoid arthritis: a controlled trial’, Br. Med. J. 1 (1976) 1052–4.
Dwosh, I. L., Stein, H. B., Urowitz, M. B., Smythe, H. A., Hunter, T. and Ogryzlo, M. A. ‘Azathioprine in early rheumatoid arthritis: comparison with gold and chloroquine’, Arthritis Rheum. 20 (1977) 685–92.
Yu, D. T., Clements, P. J., Levy, J. and Barnett, E. V. ‘Lymphocyte characteristics in rheumatic patients and the effect of azathioprine therapy’, Arthritis Rheum. 17 (1974) 37–45.
See notes 14 and 16.
Curtis, J. E., Sharp, J. T., Lidsky, M.D. and Hersh, E. M. ‘Immune response of patients with rheumatoid arthritis during cyclophosphamide treatment’, Arthritis Rheum. 16 (1973) 34–42.
Strong, J. S., Bartholomew, B. A. and Smyth, C. J. ‘Immunoresponsiveness of patients with rheumatoid arthritis receiving cyclophosphamide or gold salts’, Ann. Rheum. Dis. 32 (1973) 233–7.
Elion, G. B. ‘Biochemistry and pharmacology of purine analogues’, Federation Proc. 26 (1967) 898–904.
Jolivet, J., Cowan, K. H., Curt, G. A., Clendenhin, N. J. and Clabner, B. A. ‘The pharmacology and clinical use of methotrexate’, New Engl. J. Med. 309 (1983) 1094–104.
Groff, G. D., Shenberger, K. N., Wilks, W. S. and Taylor, T. H. ‘Low-dose oral methotrexate in rheumatoid arthritis: an uncontrolled trial and review of the literature’, Sem. Arthritis Rheum. 12 (1983) 333–47.
Gifford, R. H. and Feinstein, A. R. ‘A critique of methodology in studies of anti-coagulant therapy for acute myocardial infarction’, New Engl. J. Med. 280 (1969) 351–7.
Iannuzzi, L., Dawson, N., Zein, N. and Kushner, I. ‘Does drug therapy slow radiographic deterioration in rheumatoid arthritis?’, New Engl. J. Med. 309 (1983) 1023–8.
See notes 12 and 13.
Lidsky, M. D., Sharp, J. T. and Billings, S. ‘Double-blind study of cyclophosphamide in rheumatoid arthritis’, Arthritis Rheum. 16 (1973) 148–53.
Currey, H. L. F., Harris, J., Mason, R. M., Woodland, J., Beveridge, T., Roberts, C. J., Vere, D. W., Dixon, A. St J., Davies, J. and Owen-Smith, B. D. ‘Comparison of azathioprine, cyclophosphamide and gold in treatment of rheumatoid arthritis’, Br. Med. J. 3 (1974) 763–6.
Smyth, C. J., Bartholomew, B. A., Mills, D. M., Steigerwald, J. C., Strong, S. J. and Recart, S. ‘Cyclophosphamide therapy for rheumatoid arthritis’, Arch. Intern. Med. 135 (1975) 789–93.
Williams, H. J., Reading, J. C., Ward, J. R. and O’Brien, W. M. ‘Comparison of high- and low-dose cyclophosphamide therapy in rheumatoid arthritis’, Arthritis Rheum. 23 (1980) 521–7.
Fosdick, W. M., Parsons, J. L. and Hill, D. F. ‘Long-term cyclophosphamide therapy in rheumatoid arthritis’, Arthritis Rheum. 11 (1968) 151–61.
See notes 17, 18 and 30.
Mason, M., Currey, H. L. F., Barnes, C. G., Dunne, J. F., Hazelman, B. L. and Strickland, I. D. ‘Azathioprine in rheumatoid arthritis’, Br. Med. J. 1 (1969) 420–2.
Harris, J., Jessop, J. D. and Chaput de Saintonge, D. M. ‘Further experience with azathioprine in rheumatoid arthritis’, Br. Med. J. 4 (1971) 463–4.
Urowitz, M. B., Hunter, T., Bookman, A. A. M., Gordon, D. A., Smyth, H. A. and Ogryzlo, M. A. ‘Azathioprine in rheumatoid arthritis: a double-blind study comparing full dose to half dose’, J. Rheum. 1 (1974) 274–81.
Woodland, J., Chaput de Saintonge, D. M., Evans, S. J., Sharman, V. L. and Currey, H. L. F. ‘Azathioprine in rheumatoid arthritis: a double-blind study of full versus half doses versus placebo’, Ann. Rheum. Dis. 40 (1981) 355–9.
Urowitz, M. B., Gordon, D. A., Smythe, H. A., Purzanski, W. and Ogryzlo, M. A. ‘Azathioprine in rheumatoid arthritis. A double-blind cross-over study’, Arthritis Rheum. 16 (1973) 411–18.
Hunter, T., Urowitz, M. B., Gordon, D. A., Smythe, H. A. and Ogryzlo, M. A. ‘Azathioprine in rheumatoid arthritis: a long-term follow-up study’, Arthritis Rheum. 18 (1975) 15–20.
Goebel, K. M., Janzen, R., Joseph, K. and Borngen, U. ‘Disparity between clinical and immune responses in controlled trial of azathioprine in rheumatoid arthritis’, Eur. J. Clin. Pharmacol. 9 (1976) 405–10.
van Wanghe, P. and Dequeker, J. ‘Compliance and long-term effect of azathioprine in 65 rheumatoid arthritis cases’, Ann. Rheum. Dis. 41 (Suppl. 1) (1982) 40–3.
A Committee of the American Rheumatism Association, ‘Diagnostic criteria for rheumatoid arthritis’, Ann. Rheum. Dis. 18 (1959) 49.
Hatchuel, R. ‘Efficacité et mode d’action du chlorambucil dans la polyarthrite rheumatoide. Etude controlée en double insu. A propos de 47 observations’, Memoire pour l’obtention du certificat d’études speciales en rhumatologie (Paris: 1972 ).
See note 12.
See notes 18 and 30.
See note 18.
See note 17.
See notes 12, 13, 29, 30 and 31.
See notes 17, 18, 30, 35, 37 and 38.
See note 35.
Freiman, J. A., Chalmers, T. C., Smith, H. and Kuebler, R. R. ‘The importance of beta, the type II error and sample size in the design and interpretation of the randomised control trial. Survey of 71 ‘negative’ trials’, New Engl. J. Med. 299 (1978) 690–4.
Nicholls, A., Snaith, M. L., Maini, R. N. and Scott, J. T. ‘Controlled trial of azathioprine in rheumatoid arthritis’, Ann. Rheum. Dis. 32 (1973) 589–91.
See notes 12, 13, 30, 31 and 32.
See note 29.
See note 30.
See note 32.
See note 12.
See note 13.
See notes 12 and 30.
See notes 31 and 13.
See notes 17, 18, 30, 35, 37, 38, 39 and 41.
See notes 39 and 41.
See note 30.
See notes 39 and 17.
See note 25.
Willkens, R. F., Watson, M. A. and Paxson, C. S. ‘Low-dose methotrexate therapy in rheumatoid arthritis’, J. Rheum. 7 (1980) 501–5.
Michaels, R. M., Nashel, D. J., Leonard, A., Sliwinski, A. J. and Derbes, S. J. ‘Weekly intravenous methotrexate in the treatment of rheumatoid arthritis’, Arthritis Rheum. 25 (1982) 339–41.
Steinsson, K., Weinstein, A., Korn, J. and Abeles, M. ‘Low-dose methotrexate in rheumatoid arthritis’, J. Rheum. 9 (1982) 860–6.
Kahn, M. F., Bedoiseau, M. and de Sege, S. ‘Immunosuppressive drugs in the management of malignant and severe rheumatoid arthritis’, Proc. Roy. Soc. Med. 60 (1967) 130–3.
See note 5.
See note 44.
Schmahl, D., Habs, M., Lorenz, M. and Wagner, I. ‘Occurrence of second tumours in man after anti-cancer drug treatment’, Cancer Treatment Rev. 9 (1982) 167–94.
See note 5.
Abel, T., Andrews, B. S., Cunningham, O. H., Brunner, C. M. and Davis, J. S. and Horowitz, D. A. ‘Rheumatoid vasculitis: effect of cyclophosphamide on the clinical course and levels of circulating immune complexes’, Ann. Intern. Med. 93 (1980) 407–13.
Weisman, M. and Zvaifler, N. ‘Cryoglobulinaemia in rheumatoid arthritis. Significance in serum of patients with rheumatoid vasculitis’, J. Clin. Invest. 56 (1975) 725–39.
See note 70.
Thorpe, P., Hassal, J. E. and York, J. R. ‘Rheumatoid arthritis treated with chlorambucil. A five-year follow-up’, Med. J. Austr. 2 (1976) 197–9.
See note 53.
McCarty, D. J. and Carrera, G. F. ‘Intractable rheumatoid arthritis. Treatment with combined cyclophosphamide, azathioprine and hydroxychloroquine’, J. Am. Med. Assoc. 248 (1982) 1718–23.
See notes 13 and 31.
See note 16.
Horwitz, D. A. ‘Selective depletion of Ig-bearing lymphocytes by cyclophosphamide in rheumatoid arthritis and systemic lupus erythematosus. Guidelines for dosage’, Arthritis Rheum. 17 (1974) 363–74.
Plotz, P. H., Klippel, J. H., Decker, J. L., Grauman, K., Wolff, B., Brown, B. C. and Rutt, G. ‘Bladder complications in patients receiving cyclophosphamide for systemic lupus erythematosus or rheumatoid arthritis’, Ann. Intern. Med. 91 (1979) 221–3.
Johnson, W. W. and Meadows, D. C. ‘Urinary bladder fibrosis and telangiectasia associated with long-term cyclophosphamide therapy’, New Engl. J. Med. 284 (1971) 290–4.
See note 13.
Robinson, J. K., Baugham, R. D., Auerbach, R. and Cimis, R. J. ‘Methotrexate hepatoxicity in psoriasis. Consideration of liver biopsies at regular intervals’, Arch. Dermatol. 116 (1980) 413–5.
See note 25.
See note 3.
Sieber, S. M. and Adamson, R. H. ‘Toxicity of anti-neoplastic agents in man; chromosomal aberrations, anti-fertility effects, congenital malformations and carcinogenic potential’, Adv. Cancer Res. 22 (1975) 57–155.
See note 24.
Uldall, P. R., Kerr, D. N. S. and Tacchi, D. ‘Sterility and cyclophosphamide’, Lancet, 1 (1972) 693–4.
Warne, G. L., Fairley, K. F., Hobbs, J. B. and Martin, F. A. R. ‘Cyclophosphamide-induced ovarian failure’, New Engl. J. Med. 289 (1973) 1159–62.
See notes 90 and 92.
Harris, C. C. ‘The carcinogenicity of anti-cancer drugs: a hazard in man’, Cancer 37 (1976) 1014–23.
Cascatio, D. A. and Scott, J. L. ‘Acute leukaemia following prolonged cytotoxic agent therapy’, Medicine (Baltimore) 58 (1979) 32–47.
Berk, P. D., Goldberg, J. D., Silverstein, M. N. et al. ‘Increased incidence of acute leukaemia in polycythaemia vera associated with chlorambucil therapy’, New Engl. J. Med. 304 (1981) 441–7.
Greene, M. H., Boice, J. D., Greer, B. E., Blessing, J. H. and Dembo, A. J. ‘Acute non-lymphocytic leukaemia after therapy with alkylating agents for ovarian cancer. A study of five randomised clinical trials’, New Engl. J. Med. 307 (1982) 1416–21.
Grunwald, H. W. and Rosner, F. ‘Acute leukaemia and immunosuppressive drug use. A review of patients undergoing immunosuppressive therapy for non-neoplastic diseases’, Arch. Intern. Med. 139 (1979) 461–6.
Vismans, J. J., Briet, E., Meijer, K. and den Ottolander, G. J. ‘Azathioprine and sub-acute myelomonocytic leukaemia’, Acta Med. Scand. 207 (1980) 315–19.
Kinlen, L. J., Shell, A. G. R., Peto, J. and Doll, R. ‘Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs’, Br. Med. J. 2 (1979) 1461–6.
Kinlen, L. J., Peto, J., Doll, R. and Sheil, A. G. R. ‘Cancer in patients treated with immunosuppressive drugs’, Br. Med. J. 282 (1981) 474.
Baltus, J. A. M., Boersma, J. W., Hartman, A. P. and Vandenbrouke, J. P. ‘The occurrence of malignancies in patients with rheumatoid arthritis treated with cyclophosphamide: a controlled retrospective follow-up’, Ann. Rheum. Dis. 42 (1983) 368–73.
See notes 73 and 84.
Wall, R. L. and Clausen, K. P. ‘Carcinoma of the urinary bladder in patients receiving cyclophosphamide’, New Engl. J. Med. 293 (1975) 271–3.
See note 103.
Isomaki, H. A., Hakulinen, T. and Joutsenlahti, U. ‘Excess risk of lymphoma leukaemia and myeloma in patients with rheumatoid arthritis’, Ann. Rheum. Dis. 41 (Suppl. 1) (1982) 34–6.
Prior, P., Symmons, D. P. M., Hawkins, C. F., Scott, D. L. and Brown, R. ‘Cancer morbidity in rheumatoid arthritis’, Ann. Rheum. Dis. 43 (1984) 128–31.
Ibid.
Isomaki, H. A., Mutru, O. and Koata, K. ‘Death rate and causes of death in patients with rheumatoid arthritis’, Scand. J. Rheumatol. 4 (1975) 205–8.
Lewis, R. B., Castow, C. W., Knisley, R. E. and Bole, G. G. ‘Frequency of neoplasia in systemic lupus erythematosus and rheumatoid arthritis’, Arthritis Rheum. 19 (1976) 1256–60.
Bailin, P. L., Tindall, J. P., Roenigk, H. H. and Hogan, M. D. ‘Is methotrexate therapy for psoriasis carcinogenic? A modified retrospective-prospective analysis’, J. Am. Med. Assoc. 232 (1975) 359–62.
Rustin, G. J. S., Rustin, F., Dent, J., Booth, M., Salt, S. and Bagshawe, K. D. ‘No increase in second tumours after cytotoxic chemotherapy for gestational trophoblastic tumours’, New Engl. J. Med. 308 (1983) 473–6.
Editor information
Editors and Affiliations
Copyright information
© 1984 D. H. Goddard and R. C. Butler
About this chapter
Cite this chapter
Erhardt, C.C. (1984). Immunosuppressive therapy for rheumatoid arthritis. In: Goddard, D.H., Butler, R.C. (eds) Rheumatoid Arthritis: The Treatment Controversy. Palgrave, London. https://doi.org/10.1007/978-1-349-08808-9_5
Download citation
DOI: https://doi.org/10.1007/978-1-349-08808-9_5
Publisher Name: Palgrave, London
Print ISBN: 978-0-333-41920-5
Online ISBN: 978-1-349-08808-9
eBook Packages: MedicineMedicine (R0)